ACBM Boosts Share Count Amidst Zero Revenue, Q2 2024

TL;DR

**ACBM is burning through shares with no revenue, a speculative bet at best.**

AI Summary

ACRO BIOMEDICAL CO., LTD. (ACBM) reported no revenue for the six months ended June 30, 2024, consistent with the prior year period. The company's net loss for the six months ended June 30, 2024, was not explicitly stated with a dollar amount, but the filing indicates a focus on capital structure changes rather than operational profitability. Key business changes include the issuance of 60,042,000 shares of common stock for $0.001 per share during the six months ended June 30, 2024, significantly increasing outstanding shares. The company also issued 25,000,000 shares of Series A Preferred Stock at $0.001 per share. Risks primarily revolve around the company's lack of revenue generation and reliance on equity financing, as evidenced by the substantial stock issuances. The strategic outlook appears to be centered on securing capital through stock sales, with no clear operational growth strategy detailed in the provided data.

Why It Matters

For investors, ACBM's continued lack of revenue and reliance on dilutive equity financing, such as the issuance of 60,042,000 common shares, signals a high-risk investment with no clear path to profitability. Employees and customers are directly impacted by the company's pre-revenue status, as there are no operational activities to support jobs or deliver products/services. In a competitive market, ACBM's inability to generate revenue places it far behind established biomedical firms, making its long-term viability questionable without significant strategic shifts. The broader market should view this as a cautionary tale of early-stage companies struggling to transition from concept to commercialization.

Risk Assessment

Risk Level: high — The risk level is high due to ACBM's complete lack of revenue for the six months ended June 30, 2024, and its reliance on significant dilutive financing. The issuance of 60,042,000 common shares and 25,000,000 Series A Preferred Stock at $0.001 per share indicates a desperate need for capital without any operational income to offset it.

Analyst Insight

Investors should avoid ACBM given its zero revenue and heavy reliance on dilutive stock issuances. This company is highly speculative and lacks fundamental business operations, making it unsuitable for most portfolios.

Financial Highlights

revenue

$0

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (for the six months ended June 30, 2024, indicating no operational income.)
• 60,042,000 — Common Shares Issued (during the six months ended June 30, 2024, leading to significant shareholder dilution.)
• 25,000,000 — Series A Preferred Stock Shares Issued (at $0.001 per share, further increasing capital structure complexity and potential dilution.)
• $0.001 — Per Share Price (for both common and preferred stock issuances, highlighting the low valuation of new equity.)

Key Players & Entities

• ACRO BIOMEDICAL CO., LTD. (company) — filer of the 10-Q
• SEC (regulator) — recipient of the 10-Q filing
• $0.001 (dollar_amount) — per share price for common and preferred stock
• 60,042,000 (dollar_amount) — number of common shares issued
• 25,000,000 (dollar_amount) — number of Series A Preferred Stock shares issued
• June 30, 2024 (date) — end of the reporting period for the 10-Q
• Bloomberg (company) — financial news outlet

FAQ

Risk Factors

• Lack of Revenue Generation [high — financial]: The company reported $0 revenue for the six months ended June 30, 2024, and the prior year period. This indicates a complete absence of operational income, raising significant concerns about the company's ability to sustain itself without continuous external financing.
• Heavy Reliance on Equity Financing [high — financial]: ACBM issued 60,042,000 shares of common stock and 25,000,000 shares of Series A Preferred Stock at a nominal price of $0.001 per share during the six months ended June 30, 2024. This substantial dilution suggests a critical need for capital and a lack of alternative funding sources.
• Low Per Share Valuation [medium — financial]: The issuance of both common and preferred stock at $0.001 per share indicates a very low market valuation for the company. This could make future capital raises more challenging and may reflect investor skepticism about the company's prospects.
• Absence of Clear Business Strategy [high — operational]: The filing focuses on capital structure changes rather than detailing an operational growth strategy. Without a clear plan for revenue generation or product development, the company's long-term viability is uncertain.

Industry Context

ACRO BIOMEDICAL CO., LTD. operates within the broader biomedical sector, which is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies in this industry often rely on substantial funding rounds to advance their technologies and bring products to market. The competitive landscape includes established pharmaceutical giants and numerous innovative startups, making differentiation and successful capital acquisition crucial for survival and growth.

Regulatory Implications

As a biomedical company, ACBM is subject to stringent regulations from bodies like the FDA. Failure to comply with these regulations can lead to significant penalties, product recalls, or denial of market approval. The company's current financial state and reliance on equity financing may also attract scrutiny regarding its long-term viability and ability to meet ongoing compliance requirements.

What Investors Should Do

1. Monitor future capital raises and their terms.
2. Seek clarity on the company's operational strategy and revenue generation plan.
3. Evaluate the impact of significant share dilution on existing holdings.

Key Dates

• 2024-06-30: End of Q2 2024 — Represents the period for which the 10-Q filing provides financial data, showing $0 revenue and significant stock issuances.
• 2025-07-23: Filing Date of 10-Q — Indicates the most recent reporting date for the company's financial status and business activities.
• 2014-10-22: Date of Name Change — The company was formerly known as KILLER WAVES HAWAII, INC, indicating a significant shift in business focus or identity.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document provides the primary source of financial and operational information for ACBM.)

Series A Preferred Stock

A class of preferred stock that has priority over common stock in terms of dividends and asset distribution in case of liquidation. (ACBM issued a significant amount of this stock, impacting its capital structure and potentially diluting common shareholders.)

Shareholder Dilution

The reduction in the value of existing shareholders' equity resulting from the issuance of new shares. (ACBM's substantial stock issuances at a low price per share directly lead to significant shareholder dilution.)

Capital Structure

The mix of debt and equity a company uses to finance its operations. (The filing highlights ACBM's focus on altering its capital structure through equity issuance rather than operational improvements.)

Year-Over-Year Comparison

For the six months ended June 30, 2024, ACRO BIOMEDICAL CO., LTD. reported $0 revenue, consistent with the prior year period. The most significant change is the dramatic increase in outstanding shares due to the issuance of 60,042,000 common shares and 25,000,000 Series A Preferred Stock shares at $0.001 per share. This indicates a shift in focus towards capital acquisition through equity dilution rather than operational performance improvements, which were also absent in the prior comparable period.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on July 23, 2025 regarding ACRO BIOMEDICAL CO., LTD. (ACBM).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR